Steroids on the neonatal unit

Broad, Samuel Robin; Maxwell, Nicola C.

doi:10.1016/j.paed.2016.08.002

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To visualize the trend of DQ at 3 years of age, we conducted boxplot analysis by dividing the data into three groups according to the total HDC dosage: <10 mg, 10–20 mg, and >20 mg. Our main analysis involved using multiple linear regression to estimate the association between HDC dosage in the neonatal period and DQ at 3 years of age. The main model was constructed based on the presence or absence of BPD and LCC, which are often treated with steroid administration [ 1 , 2 ]. To examine the robustness of the primary analysis results, we conducted sensitivity analyses.…”

Section: Methodsmentioning

confidence: 99%

“…Extremely low birth weight (ELBW) infants require intensive care including various medication administrations. Postnatal steroids have mainly been used in treating hypotension, including late-onset circulatory collapse (LCC) [ 1 ], and in the prevention/treatment of bronchopulmonary dysplasia (BPD) [ 2 ]. Dexamethasone became widely used in the 1990s–2000s after reports of short-term respiratory benefits [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Total Hydrocortisone Dosage in the Neonatal Period May Be Related to Low Developmental Quotient in Extremely Low Birth Weight Infants: A Retrospective Cohort Study

Taniguchi,

Nishida,

Suzuki

et al. 2023

Neonatology

View full text Add to dashboard Cite

Introduction: The effects of hydrocortisone (HDC) administration to extremely low birth weight (ELBW) infants on later development remain unclear. This study examined the association between HDC dosage during neonatal period and neurodevelopmental outcomes in ELBW infants. Methods: This study was a retrospective cohort study conducted in eight centers in Japan. The subjects of this study were ELBW infants born between April 2015 and March 2017. The association between postnatal total HDC dosage up to 36 weeks postmenstrual age and the developmental quotient (DQ) at 3 years of age was examined. Multiple linear regression evaluated the association, adjusting for weeks of gestation, birth weight, and the presence of bronchopulmonary dysplasia, late-onset circulatory collapse, intracranial hemorrhage, necrotizing enterocolitis, and sepsis. Results: This study included 218 ELBW infants, of whom 144 underwent a developmental test at 3 years of age. Simple linear regression analysis revealed a significant association between total HDC dosage and DQ at 3 years of age (coefficients: −2.65, 95% CI: −3.73, −1.57). Multiple linear regression analysis adjusted for the presence of bronchopulmonary dysplasia and late-onset circulatory collapse also revealed a significant association between total HDC dosage and DQ at 3 years of age (coefficients: −2.66, 95% CI: −3.89, −1.42). Conclusion: Higher total HDC dosage up to 36 weeks postmenstrual age in ELBW infants was associated with impaired neurodevelopmental outcomes. Although HDC is often needed in the treatment of ELBW infants, clinicians should be aware that an increased dose of HDC may be associated with impaired neurodevelopmental outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%